A non-linear mixed-effects model to describe the effect of acarbose intake on postprandial glycaemia in a single rat

Omar Cléo Neves Pereira,Paulo Vitor Da Costa Pereira,Isolde Previdelli,Rosangela Santana,Emerson Barili,Mauricio Fumio Sybuia

doi:10.4025/actascihealthsci.v39i1.27431

Omar Cléo Neves Pereira, Paulo Vitor Da Costa Pereira + Show 4 more

Open Access

https://doi.org/10.4025/actascihealthsci.v39i1.27431

Copy DOI

Abstract

A non-linear mixed-effects model is proposed to assess the impact of acarbose over time on postprandial glycaemia in a single rat. The model is based on two compartments, one representing the entry of glucose in the blood and the other its exit. The rat was submitted to two treatments: ingestion of starch and ingestion of starch plus acarbose. The model showed great suitability, with inferences on the behavior of glucose levels in response to treatments and supplying a richer description than just the area under the curve. The marginal curves for the two treatments are similar during the first moments; however, after reaching the peak of glucose concentration, they progressively became separate due to acarbose treatment and reached the initial levels more quickly. The proposed model, albeit with a single sample unit, showed similar results to those with larger samples; in other words, acarbose significantly attenuates glycaemia after ingestion of starch.

Highlights

The metabolic disease diabetes mellitus is among the ten mortality causes in populations worldwide
Acarbose has been widely studied for the treatment of Type 2 diabetes (Ritz et al, 2012; Rosak, Haupt, Walter, & Werner, 2002; Yee & Fong, 1996) as a therapeutic agent added to food or as a drug administered orally (Espín, García-Conesa, & Tomás-Barberán, 2007; Eng Kiat Loo & Huang, 2007)
With only one experimental unit, it was possible to obtain results similar to those of other studies which reported the effect of acarbose on glycaemia carried out with larger samples (Coniff et al, 1995; Pereira et al, 2011; Ritz et al, 2012; Rosak et al, 2002; Scheen et al, 1994; Sybuia et al, 2014-2015; Wong & Jenkins, 2007; Yee & Fong, 1996)

Summary

Introduction

The metabolic disease diabetes mellitus is among the ten mortality causes in populations worldwide. The high cost of the disease demands that public and private health systems investigate new treatments, intervention programs (Ejtahed et al, 2012; König, Kookhan, Schaffner, Deibert, & Berg, 2014; Shen, Obin, & Zhao., 2013; Costa & Longo, 2014) and drugs capable to improve the patients' quality of life. Acarbose has been widely studied for the treatment of Type 2 diabetes (Ritz et al, 2012; Rosak, Haupt, Walter, & Werner, 2002; Yee & Fong, 1996) as a therapeutic agent added to food or as a drug administered orally (Espín, García-Conesa, & Tomás-Barberán, 2007; Eng Kiat Loo & Huang, 2007)

Methods

Results

Conclusion